ALXO
NASD ALX Oncology Holdings, Inc.$1.06 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.06, $0.10 below the day’s high of $1.16
- YTD change
- -6.19%
- vs 20-day SMA
- -17.70%
- vs 200-day SMA
- -42.01%
Price ranges
Price & Performance
-0.62 (-36.90%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.1% away from all-time highs of $117.45
- ALXO is down 6% since the beginning of the year
- ALXO is down 36% over the past 12 months
- ALXO is down 39% over the past 1 month
- 4% of all ALXO investors are betting against ALXO
ALXO reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -35.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.04
- Last 5 days
- -10.17%
- vs 8-day SMA
- -3.68%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
ALX Oncology Holdings, Inc. is a clinical-stage biotechnology company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
